Adaptive Biotechnologies (ADPT) Surges 9.94% on Session 49.23% Weekly Rally Driven by ASH 2025 clonoSEQ Momentum

The share price rose to its highest level so far this month, with an intraday gain of 10.96%. Adaptive Biotechnologies (ADPT) extended its five-day winning streak, surging 9.94% on the session to mark a 49.23% rally over the past week. The rally follows a record-breaking presence at the upcoming ASH 2025 conference, where clonoSEQ—the company’s MRD diagnostic test—is featured in 89 abstracts, including 36 oral presentations. This unprecedented visibility underscores clonoSEQ’s growing role in hematologic oncology, positioning it as a standard-of-care tool for monitoring residual disease in cancers like multiple myeloma, leukemia, and lymphoma.

Adaptive’s stock performance reflects investor optimism about clonoSEQ’s expanding applications and clinical validation. The test’s FDA clearance for multiple myeloma and B-cell acute lymphoblastic leukemia, alongside CLIA-validated use in other malignancies, has solidified its market position. Over 17 presentations at ASH will highlight how clonoSEQ directly informs treatment decisions in real-world settings, reinforcing its value in personalized medicine. The test’s integration into clinical trials for novel therapies, including CAR T-cell and bispecific antibodies, further enhances its commercial potential by aligning with drug development pipelines.

Regulatory milestones and industry recognition have amplified Adaptive’s strategic momentum. As the first and only FDA-cleared NGS-based MRD test for certain indications, clonoSEQ faces minimal competition, creating a durable moat. The ASH conference, a key platform for scientific validation, strengthens the test’s credibility among clinicians and payers, likely driving adoption and revenue growth. Despite current profitability challenges, Adaptive’s focus on margin expansion and its leadership in immune-driven medicine position it to capitalize on the rising demand for precision oncology tools. The stock’s recent surge suggests investors are pricing in long-term value from clonoSEQ’s clinical utility and market expansion.